Gujarat Themis Biosyn Announces 45th AGM on Sep 30, 2026, Approves Preferential Issue
Gujarat Themis Biosyn will hold its 45th AGM on September 30, 2026. The company proposes a preferential issue of equity shares worth ₹335 crore and plans to raise funds through loans and guarantees from promoters. Approvals are also sought for director commission payments and cost auditor remuneration.
The preferential issue of over ₹335 crore and the potential for large-scale debt fundraising from promoters will significantly impact the company's capital structure, growth trajectory, and shareholder base. The AGM agenda covers multiple critical financial and corporate decisions.
The announcement includes significant positive corporate actions such as a substantial preferential issue to fund growth and acquisitions, alongside the approval of loans and guarantees from promoters, indicating a proactive approach to expansion and financial strategy.
Gujarat Themis Biosyn Limited has announced its 45th Annual General Meeting (AGM) to be held on Wednesday, September 30, 2026, at 12:30 PM in Vapi, Gujarat. The meeting will cover ordinary businesses including the adoption of audited financial statements for the fiscal year ended March 31, 2026, the reappointment of a retiring director, and the declaration of dividends. Special businesses include the ratification of remuneration for the cost auditor, M/s. Raja Dutta & Co., for the financial year 2026-27 at Rs. 50,000 plus taxes. The company also seeks approval for the payment of commission to Non-Executive Chairman, Dr. Dinesh S. Patel, amounting to Rs. 42,00,000, and to Managing Director, Dr. Sachin D. Patel, amounting to Rs. 65,00,000 for the financial year ended March 31, 2026.
Furthermore, the company intends to approve availing loans and guarantees from Promoters/Promoter Group to finance acquisition and growth opportunities. The Board of Directors has also proposed a preferential issue of up to 82,10,786 equity shares at Rs. 408 per share, aggregating up to Rs. 335,00,00,688. The proposed allottees include Pharmaceutical Business Group (India) Limited, Yusuf Khwaja Hamied, Special Situation India Fund, India Special Assets Fund III, and ISAF III Onshore Fund. The relevant date for determining the floor price is August 31, 2026.
The company is seeking shareholder approval for these significant corporate actions through ordinary and special resolutions at the upcoming AGM.
A plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.
